JAC Advance Access originally published online on July 22, 2005
Journal of Antimicrobial Chemotherapy 2005 56(3):532-537; doi:10.1093/jac/dki258
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Invasive Candida species infections: a 5 year population-based assessment
1 Department of Medicine, Calgary Health Region and University of Calgary, Calgary, Alberta, Canada; 2 Department of Pathology and Laboratory Medicine, Calgary Health Region and University of Calgary, Calgary, Alberta, Canada; 3 Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; 4 The Centre for Anti-Microbial Resistance, Calgary Health Region, University of Calgary, and Calgary Laboratory Services, Room 1W-415, #9, 3535 Research Road NW, Calgary, Alberta, Canada T2L 2K8; 5 Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada
Received 11 May 2005; returned 6 June 2005; revised 9 June 2005; accepted 23 June 2005
* Corresponding author. Tel: +1-403-770-3346; Fax: +1-403-770-3347; E-mail: kevin.laupland{at}calgaryhealthregion.ca
Objectives: Candida species have emerged as important causes of invasive infections and rates of resistance to standard antifungal therapies are rising. The objective of this study was to define the occurrence of, risk factors for, and antifungal susceptibilities of invasive Candida species infections in a large Canadian health region.
Methods: Population-based surveillance was conducted for invasive Candida species infections in the Calgary Health Region during a 5 year period and susceptibility testing was performed.
Results: The annual incidence of invasive Candida species infection was 2.9 per 100 000 population (0.2 and 2.8 per 100 000 for central nervous system and bloodstream infection, respectively). The very young and elderly were at highest risk for invasive Candida species infections. Several risk factors for developing invasive Candida species infection were identified with chronic haemodialysis, organ transplant recipient, and cancer patients at highest risk. Thirty percent (56/184; 43 susceptible, dose-dependent and 13 resistant) of isolates demonstrated reduced susceptibility to fluconazole. Only one (1%) isolate had reduced susceptibility to amphotericin B and six (3%) and three (2%) isolates had minimum inhibitory concentrations of 
1 mg/L to voriconazole and caspofungin, respectively. Overall, 40% of patients died in-hospital for an annual mortality rate of 1.2 per 100 000.
Conclusions: Candida species are an important cause of invasive infection and patients with co-morbidities and extremes of age are at highest risk. Alternatives to fluconazole should be considered for initial empiric therapy in patients with severe invasive Candida species infections.
Keywords: candidaemia , mortality , susceptibility
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. C. Arendrup, G. Garcia-Effron, C. Lass-Florl, A. G. Lopez, J.-L. Rodriguez-Tudela, M. Cuenca-Estrella, and D. S. Perlin Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media Antimicrob. Agents Chemother., January 1, 2010; 54(1): 426 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller, S. A. Messer, R. J. Hollis, L. Boyken, S. Tendolkar, J. Kroeger, and D. J. Diekema Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007 J. Clin. Microbiol., October 1, 2009; 47(10): 3185 - 3190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Arendrup, G. Garcia-Effron, W. Buzina, K. L. Mortensen, N. Reiter, C. Lundin, H. E. Jensen, C. Lass-Florl, D. S. Perlin, and B. Bruun Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1185 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Gonzalez, M. Elizondo, and J. Ayala Trends in Species Distribution and Susceptibility of Bloodstream Isolates of Candida Collected in Monterrey, Mexico, to Seven Antifungal Agents: Results of a 3-Year (2004 to 2007) Surveillance Study J. Clin. Microbiol., September 1, 2008; 46(9): 2902 - 2905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Parkins, D. M. Sabuda, S. Elsayed, and K. B. Laupland Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections J. Antimicrob. Chemother., September 1, 2007; 60(3): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Odds, M. F. Hanson, A. D. Davidson, M. D. Jacobsen, P. Wright, J. A. Whyte, N. A. R. Gow, and B. L. Jones One year prospective survey of Candida bloodstream infections in Scotland J. Med. Microbiol., August 1, 2007; 56(8): 1066 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Church, S. Elsayed, O. Reid, B. Winston, and R. Lindsay Burn Wound Infections Clin. Microbiol. Rev., April 1, 2006; 19(2): 403 - 434. [Abstract] [Full Text] [PDF]
|
|